Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9216642 | 0.93 | AKR1B1 (0.58) | AKR1B1ALDH1A1MAPTHRH1SMN1; SMN2 | |
| SCHEMBL9216257 | 0.88 | AKR1B1 (0.56) | AKR1B1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9215390 | 0.88 | AKR1B1 (0.56) | AKR1B1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12796661 | 0.87 | ALDH1A1 (0.63) | AKR1B1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| Isoxepac SCHEMBL29588437 | 0.86 | AKR1B1 (0.81) | AKR1B1ALDH1A1MAPTRAB9AHRH1 | |
| Isoxepac SCHEMBL24970 | 0.86 | AKR1B1 (0.81) | AKR1B1ALDH1A1MAPTRAB9AHRH1 | |
| SCHEMBL9219969 | 0.85 | AKR1B1 (0.63) | AKR1B1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL342988 | 0.85 | AKR1B1 (0.63) | AKR1B1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL11085181 | 0.84 | ALDH1A1 (0.57) | AKR1B1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4008419 | 0.84 | ALDH1A1 (0.60) | AKR1B1ALDH1A1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | claimed |
| EP-2145882-A1 | Process for obtaining olopatadine and intermediates | Ragactives, S.L.U. (ES) | 2010-01-20 | — | — | EP | claimed |
| US-9000195-B2 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA, S.A.U. (ES) | 2015-04-07 | — | — | US | disclosed |
| US-9000195-B2 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA, S.A.U. (ES) | 2015-04-07 | — | — | US | disclosed |
| US-9000195-B2 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA, S.A.U. (ES) | 2015-04-07 | — | — | US | disclosed |
| EP-2666770-A1 | Process for obtaining olopatadine and intermediates | Crystal Pharma S.A.U (ES) | 2013-11-27 | — | — | EP | disclosed |
| EP-2145882-B1 | Process for obtaining olopatadine and intermediates | CRYSTAL PHARMA SAU (ES) | 2013-08-21 | — | — | EP | disclosed |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2012-01-05 | — | — | US | disclosed |
| WO-2010007056-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | RAGACTIVES, S.L.U. (ES) | 2010-01-21 | — | — | WO | disclosed |
| EP-2145882-A1 | Process for obtaining olopatadine and intermediates | Ragactives, S.L.U. (ES) | 2010-01-20 | — | — | EP | disclosed |
| US-4816591-A | 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives | AMERICAN HOECHST CORPORATION (US) | 1989-03-28 | — | — | US | disclosed |
| US-4585788-A | 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives | AMERICAN HOECHST CORPORATION (US) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004426-A1 | PROCESS FOR OBTAINING OLOPATADINE AND INTERMEDIATES | OXER1, AOC3, OPRD1 | AKR1B1 329/4885ALDH1A1 379/4885MAPT 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.